DE69816997D1 - Mittel, die fein verteilte, kristalline budenosid-partikel enthalten - Google Patents

Mittel, die fein verteilte, kristalline budenosid-partikel enthalten

Info

Publication number
DE69816997D1
DE69816997D1 DE69816997T DE69816997T DE69816997D1 DE 69816997 D1 DE69816997 D1 DE 69816997D1 DE 69816997 T DE69816997 T DE 69816997T DE 69816997 T DE69816997 T DE 69816997T DE 69816997 D1 DE69816997 D1 DE 69816997D1
Authority
DE
Germany
Prior art keywords
budenoside
agents
particles
contain fine
fine distributed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69816997T
Other languages
English (en)
Other versions
DE69816997T2 (de
Inventor
Mikael Bisrat
Saeed Moshashaee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of DE69816997D1 publication Critical patent/DE69816997D1/de
Publication of DE69816997T2 publication Critical patent/DE69816997T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69816997T 1997-05-23 1998-05-15 Mittel, die fein verteilte, kristalline budenosid-partikel enthalten Expired - Lifetime DE69816997T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9701956A SE9701956D0 (sv) 1997-05-23 1997-05-23 New composition of matter
SE9701956 1997-05-23
PCT/SE1998/000908 WO1998052544A1 (en) 1997-05-23 1998-05-15 Composition comprising finely divided, crystalline particles of budesonide

Publications (2)

Publication Number Publication Date
DE69816997D1 true DE69816997D1 (de) 2003-09-11
DE69816997T2 DE69816997T2 (de) 2004-07-22

Family

ID=20407079

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69816997T Expired - Lifetime DE69816997T2 (de) 1997-05-23 1998-05-15 Mittel, die fein verteilte, kristalline budenosid-partikel enthalten

Country Status (28)

Country Link
US (2) US6346523B1 (de)
EP (1) EP1005328B1 (de)
JP (1) JP2001525850A (de)
KR (1) KR100514971B1 (de)
CN (1) CN1146406C (de)
AR (1) AR015820A1 (de)
AT (1) ATE246492T1 (de)
AU (1) AU734763B2 (de)
BR (1) BR9808812A (de)
CA (1) CA2290538C (de)
DE (1) DE69816997T2 (de)
DK (1) DK1005328T3 (de)
EE (1) EE03850B1 (de)
ES (1) ES2205496T3 (de)
HU (1) HUP0002212A3 (de)
ID (1) ID24332A (de)
IL (1) IL133098A (de)
IS (1) IS5254A (de)
NO (1) NO995540L (de)
NZ (1) NZ500852A (de)
PL (1) PL336902A1 (de)
PT (1) PT1005328E (de)
SE (1) SE9701956D0 (de)
SK (1) SK158799A3 (de)
TR (1) TR199902880T2 (de)
TW (1) TW518236B (de)
WO (1) WO1998052544A1 (de)
ZA (1) ZA984127B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0810853B1 (de) * 1995-02-24 2004-08-25 Elan Pharma International Limited Nanopartikel-dispersionen enthaltende aerosole
CN1192810C (zh) 2000-03-03 2005-03-16 贝林格尔·英格海姆药物公司 通过反复的溶剂膨胀－收缩处理物料
EP1354581A4 (de) * 2000-12-26 2007-07-04 Takeda Pharmaceutical Poröse substanz und verfahren zu ihrer herstellung
GB0106403D0 (en) * 2001-03-15 2001-05-02 Pharmaceutical Profiles Labelling of dry powder formulations for inhalation
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
CA2456806C (en) 2001-08-08 2011-10-18 Brown University Research Foundation Methods for micronization of hydrophobic drugs
DK1435916T3 (da) * 2001-10-10 2006-08-21 Boehringer Ingelheim Pharma Pulverbearbejdning med tryksatte gasformige fluider
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
GB0216562D0 (en) * 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
CA2523035C (en) 2003-05-22 2011-04-26 Elan Pharma International Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
EP1730751B1 (de) * 2004-03-12 2009-10-21 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Magnetoresistives medium
US20090186088A1 (en) * 2005-03-18 2009-07-23 Nanomaterials Technology Pte Ltd Inhalable drug
EP1904219A4 (de) 2005-07-15 2011-07-27 Map Pharmaceuticals Inc Teilchenbildungsverfahren
EP1782839A1 (de) 2005-11-03 2007-05-09 Genetic S.p.A. Verfahren zur Sterilisation von Glucocorticosteroiden mit überkritischem CO2
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070178051A1 (en) * 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
JP2009526860A (ja) * 2006-02-15 2009-07-23 ティカ レーケメデル アーベー 安定したコルチコステロイド混合物
US8148377B2 (en) 2007-02-11 2012-04-03 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US20100294986A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Supercritical fluid facilitated particle formation in microfluidic systems
US20100298602A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Systems and methods for microfluidic crystallization
CA2812263A1 (en) * 2010-09-22 2012-03-29 Map Pharmaceuticals, Inc. Corticosteroid particles and method of production
CN102975731B (zh) * 2012-04-24 2015-08-12 南车南京浦镇车辆有限公司 轨道车辆司机室骨架与车体的安装结构
WO2021219230A1 (en) 2020-04-30 2021-11-04 Paolo Fiorina Antiviral treatment
KR102567655B1 (ko) 2020-11-13 2023-08-17 주식회사 비츠로이엠 진공커패시터 및 진공커패시터 제조 방법
KR20230072023A (ko) 2021-11-17 2023-05-24 주식회사 비츠로이엠 가변형 진공 커패시터의 나선형 전극 위치 결정구조
KR20230072022A (ko) 2021-11-17 2023-05-24 주식회사 비츠로이엠 가변형 진공 커패시터

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282405C (en) 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
AU624421B2 (en) 1988-10-05 1992-06-11 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
DE69112917T2 (de) 1990-06-15 1996-05-15 Merck & Co Inc Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse.
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
ATE213946T1 (de) * 1991-12-18 2002-03-15 Formoterol und budesonide enthaltende zusammensetzung
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles

Also Published As

Publication number Publication date
ID24332A (id) 2000-07-13
CN1146406C (zh) 2004-04-21
ATE246492T1 (de) 2003-08-15
AU7680098A (en) 1998-12-11
CN1257424A (zh) 2000-06-21
US6346523B1 (en) 2002-02-12
IL133098A (en) 2005-03-20
SE9701956D0 (sv) 1997-05-23
TW518236B (en) 2003-01-21
TR199902880T2 (xx) 2000-02-21
DE69816997T2 (de) 2004-07-22
HUP0002212A2 (hu) 2000-12-28
AR015820A1 (es) 2001-05-30
SK158799A3 (en) 2000-05-16
DK1005328T3 (da) 2003-11-17
US6468994B2 (en) 2002-10-22
BR9808812A (pt) 2000-07-18
US20020037257A1 (en) 2002-03-28
WO1998052544A1 (en) 1998-11-26
KR20010012821A (ko) 2001-02-26
CA2290538A1 (en) 1998-11-26
NZ500852A (en) 2001-07-27
KR100514971B1 (ko) 2005-09-15
HUP0002212A3 (en) 2001-04-28
EE03850B1 (et) 2002-10-15
CA2290538C (en) 2007-01-02
IS5254A (is) 1999-11-18
EE9900533A (et) 2000-06-15
PT1005328E (pt) 2003-11-28
EP1005328B1 (de) 2003-08-06
EP1005328A1 (de) 2000-06-07
ZA984127B (en) 1998-11-23
ES2205496T3 (es) 2004-05-01
AU734763B2 (en) 2001-06-21
IL133098A0 (en) 2001-03-19
NO995540D0 (no) 1999-11-12
NO995540L (no) 1999-11-12
PL336902A1 (en) 2000-07-17
JP2001525850A (ja) 2001-12-11

Similar Documents

Publication Publication Date Title
DE69816997D1 (de) Mittel, die fein verteilte, kristalline budenosid-partikel enthalten
DE69824632D1 (de) Purinderivate und medikamente, welche dieselben als aktiven bestandteil enthalten
DE69521082D1 (de) Metallisches bakterizides Mittel
ATE378059T1 (de) Pharmazeutische zusammensetzungen mit verzoegerter freisetzung, die wasserunloesliche komplexverbindungen enthalten
HK1017995A1 (en) Compounds and compositions for delivering active agents.
DE69509134D1 (de) Doppelbankspeicher und systeme, die diesen benutzen
DE69718392T2 (de) Röntgenszintillatoren und Vorrichtungen, die diese enthalten
BR9605819A (pt) Apoio para cabeça
DE69305615T2 (de) Parfümiertes mittel
ID21762A (id) Formulasi partikel bersaput
HUP9901685A3 (en) Colchicine derivatives, the use thereof and formulations containing them
DE69912449D1 (de) Schweisshemmende mittel und zusammensetzungen die diese enthalten
DE69714213T2 (de) Synergistische Organomolybdänumzusammensetzungen und Schmiermittelzusammensetzungen die diese enthalten
DE69727711D1 (de) N-alkyl-ammonium-acetonitril-salze, methoden dazu und zusammensetzungen die diese enthalten
DE59102620D1 (de) Feste orale Applikationsformen, die als Wirkstoff Ifosfamid enthalten.
DE69811651T2 (de) Enthaarungszusammensetzungen, die bereitung und die verwendung derselben
KR950031875U (ko) 다용도 폭음기
DE9415428U1 (de) Teilchenentferner
DE9419129U1 (de) Durchlaufbrecher, insbesondere Durchlauf-Backenbrecher
ES1024288Y (es) Pinza para la sujecion de toallas y similares.
ES1021312Y (es) Dosificador de alginato para uso odontologico.
ES1031512Y (es) Soporte para bolsas perfeccionado.
ES1031126Y (es) Contenedor para objetos personales perfeccionado.
ZA986139B (en) Sulphonamide compounds, processes for their preparation, pharmaceutical compositions containing the same and their use in therapy.
ES1020489Y (es) Brocha perfeccionada y soporte para la misma.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition